Getting your Trinity Audio player ready...
|
A strategic partnership was established between a company specialising in non-invasive diabetes management solutions and a leading science and technology firm, with the support of the Hong Kong Science and Technology Parks Corporation (HKSTP). This collaboration is set to expand the availability of advanced diabetes and obesity care solutions to global markets, significantly contributing to the acceleration of innovation in these fields.
At the core of this partnership is an innovative non-invasive breath ketone management system that leverages photonic sensing technology to measure breath acetone, providing a pain-free alternative to traditional blood testing methods. The system follows a ‘one test, one kit’ model, akin to blood prick tests, which effectively reduces the risk of carryover contamination. The use of single-use breath samplers further enhances hygiene, making this solution particularly suitable for point-of-care settings. This advanced technology represents a significant step forward in the management of diabetes and related lifestyle conditions.
The CEO and Founder of the company behind the breath ketone management system emphasised the revolutionary nature of this solution in the context of diabetes and lifestyle management. The system is designed to offer a non-invasive and efficient method that improves patient care and health outcomes. The partnership with the science and technology firm, facilitated by HKSTP, marks a pivotal moment in the company’s journey. It not only broadens access to non-invasive diabetes management solutions but also accelerates progress in the fields of diabetes and obesity care. The CEO expressed excitement about the collaboration’s potential to set new standards in healthcare innovation and to continually push the boundaries of what is possible in the management of these conditions.
The Managing Director of the science and technology company highlighted the significance of this partnership in advancing patient health. As a company rooted in science and technology, there is a strong belief in the importance of collaboration to promote the best-emerging solutions that enhance diabetic care. The partnership is seen as an opportunity to provide solutions that extend beyond traditional medication, benefiting patients and having a positive impact on the broader community. The Managing Director also underscored that this strategic partnership is reinforced by a longstanding relationship with HKSTP, which aims to accelerate the commercialisation of innovative diabetes management solutions and potentially transform the landscape of care for patients.
The Head of the Institute for Translational Research at HKSTP expressed enthusiasm about the collaboration, noting that it will enable the innovative healthcare solution to reach a wider customer base and make a more significant impact on the community. HKSTP remains committed to fostering healthcare innovation and supporting groundbreaking advancements through partnerships like this one. The introduction of this collaboration was seen as a precursor to a day of important revelations and collaborative discussions.
HKSTP’s role in this partnership underscores its dedication to helping park companies expand their sales networks and improve their visibility and connectivity with industry leaders. The company behind the breath ketone management system brings professional expertise, rich industry experience, and world-class technology to the table. This strategic partnership exemplifies the vibrant innovation and technology (I&T) ecosystem in Hong Kong, which attracts high-potential startups, accelerates their growth, and ultimately brings widespread benefits to patients. This collaboration further strengthens Hong Kong’s position as a global hub for biomedical innovation, showcasing the city’s ability to drive significant advancements in healthcare through strategic alliances and cutting-edge technology.
This partnership not only enhances access to advanced non-invasive diabetes management solutions on a global scale but also positions Hong Kong as a leader in biomedical innovation, fostering a dynamic ecosystem that supports the growth and success of pioneering healthcare startups.